TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3093556

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 2 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29525076

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7213
Study: 27475339

Group type: EXPERIMENTAL
Intervention: Health promotion programme (on-the-job training 20 hours and two workshops 8 hours)
Number of subjects: 925

Group type: COMPARATOR
Intervention: Waiting control arm
Number of subjects: 925
Study: 24896266

Group type: EXPERIMENTAL
Intervention: Medical therapy (MT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PTCA) without stent
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (BMS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (DES)
Number of subjects: 15
Study: 22233510

Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK) intervention, consisting of 16 lessons of 50 min each, incorporating Cognitive Behavioral Therapy, social skills training, problem solving, and decision making.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control condition)
Number of subjects: 0
Study: 20579510

Group type: EXPERIMENTAL
Intervention: Extended-release fluvoxamine (fluvoxamine ER) 100 mg/d, titrated to 100-300 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended-release fluvoxamine (fluvoxamine ER) during 40-week open-label extension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improvement in OCD severity at 12 weeks
Number of subjects: 0
Study: 18321791

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.4 to 7.2 microg/kg)
Number of subjects: 44
Study: 16104906

Group type: EXPERIMENTAL
Intervention: Low-dose thalidomide (200 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-dose thalidomide (800 mg to 1200 mg)
Number of subjects: 14
Study: 12559480

Group type: EXPERIMENTAL
Intervention: 200‐mg L‐5‐hydroxytryptophan
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10424679

Group type: EXPERIMENTAL
Intervention: Fabric material stroked across the test site (VELVET, COTTON, PLASTIC MESH) at various velocities (0.5, 5, and 50 cm/s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Velocity of motion (0.5, 5, and 50 cm/s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replication of stimulus
Number of subjects: 0
Study: 7750006

Group type: EXPERIMENTAL
Intervention: Parietaria antigen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2242106

Group type: EXPERIMENTAL
Intervention: Phenobarbital (4 to 5 mg per kilogram of body weight per day)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Phenobarbital (after tapering and discontinuation)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 400110

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg three times daily for 10 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1000 mg three times daily for 10 days
Number of subjects: 99
Study: 30521129

Group type: EXPERIMENTAL
Intervention: PUR0200 (3 μg tiotropium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spiriva HH (18 μg)
Number of subjects: 0
Study: 26991917

Group type: EXPERIMENTAL
Intervention: Enalapril + 0.8 mg folic acid
Number of subjects: 20702

Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 20702

Group type: COMPARATOR
Intervention: Enalapril alone (MTHFR TT genotype)
Number of subjects: 20702

Group type: EXPERIMENTAL
Intervention: Enalapril + 0.8 mg folic acid (MTHFR TT genotype with low folate levels)
Number of subjects: 20702
Study: 25645353

Group type: EXPERIMENTAL
Intervention: MRD level reduction
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: MRD level as a continuous variable determined by flow cytometry
Number of subjects: 397
Study: 24352403

Group type: EXPERIMENTAL
Intervention: Intensified, NT-proBNP-guided therapy
Number of subjects: 499

Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 499
Study: 23053645

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg and 900 mg
Number of subjects: 420
Study: 19775450

Group type: EXPERIMENTAL
Intervention: Olanzapine (O) 10 mg p.o. plus azasetron (A) 10 mg i.v. and dexamethasone (D) 10 mg i.v. on day 1; O 10 mg once a day on days 2‐5
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (A 10 mg i.v. and D 10 mg i.v. on day 1; D 10 mg i.v. once a day on days 2‐5)
Number of subjects: 229
Study: 17530963

Group type: EXPERIMENTAL
Intervention: Dry-land strength training (S)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Resisted- and assisted-sprint (RAS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 21
Study: 15296584

Group type: EXPERIMENTAL
Intervention: Best Start program (experimental group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 11402109

Group type: EXPERIMENTAL
Intervention: Low-dose botulinum toxin type A (50 U)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: High-dose botulinum toxin type A (100 U)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 133
Study: 9250554

Group type: EXPERIMENTAL
Intervention: Diltiazem CD 180 mg once/day
Number of subjects: 172
Study: 8112440

Group type: EXPERIMENTAL
Intervention: LTE4
Number of subjects: 20

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: LTC4
Number of subjects: 20
Study: 3318957

Group type: EXPERIMENTAL
Intervention: Intensive Intervention Dietary Group (reduction in dietary fat intake)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control Dietary Group (dietary fat intake unchanged)
Number of subjects: 49
Study: 31710340

Group type: EXPERIMENTAL
Intervention: TPI-287 (6.3 mg/m2 for AD, 20.0 mg/m2 for 4RT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: TPI-287
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 30289569

Group type: EXPERIMENTAL
Intervention: Peri-implant mucositis
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Peri-implantitis
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Implants with bone level ≥2 mm without BOP
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Peri-implant diseases overall
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Statistically significant associations for peri-implantitis
Number of subjects: 275
Study: 26863867

Group type: EXPERIMENTAL
Intervention: Intensified physiotherapy program consisting of endurance and muscle force exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 60
Study: 25240705

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W), up-titrated to 150 mg Q2W if LDL-C ≥70 mg/dL after 8 weeks
Number of subjects: 966

Group type: COMPARATOR
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 966
Study: 22153132

Group type: COMPARATOR
Intervention: Fentanyl 0 μg with 0.17% ropivacaine 12 mL
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 μg with 0.17% ropivacaine 12 mL
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fentanyl 75 μg with 0.17% ropivacaine 12 mL
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fentanyl 100 μg with 0.17% ropivacaine 12 mL
Number of subjects: 102
Study: 20669311

Group type: EXPERIMENTAL
Intervention: CEP-1347 (antiapoptotic agent)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: CEP-1347
Number of subjects: 806
Study: 17179874

Group type: EXPERIMENTAL
Intervention: Development of a treatment fidelity instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Possibilities Project Psychotherapy Coding Questionnaire
Number of subjects: 0
Study: 16344433

Group type: EXPERIMENTAL
Intervention: Treatment for choroidal melanoma
Number of subjects: 2320
Study: 11873007

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 9876212

Group type: EXPERIMENTAL
Intervention: Fixed combination of rifampicin, co-trimoxazole and isoniazid (CotrifazidTM, CF) for 5 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Chloroquine or pyrimethamine/sulphadoxine (control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Fixed combination of rifampicin, co-trimoxazole and isoniazid (CotrifazidTM, CF)
Number of subjects: 61
Study: 7675568

Group type: EXPERIMENTAL
Intervention: Biofeedback training (8 sessions over 4 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 2123901

Group type: EXPERIMENTAL
Intervention: Conservative strategy in tertiary hospitals
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Conservative strategy in community hospitals
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Conservative strategy
Number of subjects: 1461
Study: 6994679

Group type: EXPERIMENTAL
Intervention: New synthetic dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional topical chemotherapeutic agent
Number of subjects: 0
Study: 31650480

Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity physical activity intervention
Number of subjects: 46
Study: 29956903

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) combined with psychological intervention (PI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Psychological intervention (PI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Electro-acupuncture (EA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) plus psychological intervention (PI)
Number of subjects: 120
Study: 25774566

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice daily
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 23062523

Group type: EXPERIMENTAL
Intervention: Routine care plus 6 months of daily educational text messages
Number of subjects: 659

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 659
Study: 21957161

Group type: EXPERIMENTAL
Intervention: Social technology restriction
Number of subjects: 21
Study: 19300157

Group type: EXPERIMENTAL
Intervention: Enucleation and hydroxyapatite implantation (group 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Evisceration with scleral quadrisection and alloplastic implantation (group 1)
Number of subjects: 100
Study: 17713334

Group type: EXPERIMENTAL
Intervention: Fluoridated food item (0.5 mg fluoride cookie, 3 times daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo food item (cookie, 3 times daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste
Number of subjects: 10
Study: 15025742

Group type: EXPERIMENTAL
Intervention: Trimethoprim (160 mg orally twice daily for 3 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11780763

Group type: EXPERIMENTAL
Intervention: Epicatechin gallate (ECg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epigallocatechin (EGC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antioxidant activity (FRAP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Uric acid levels
Number of subjects: 10
Study: 9517735

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 140

Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 140
Study: 8002338

Group type: EXPERIMENTAL
Intervention: serial sun‐like UV irradiation
Number of subjects: 74
Study: 3903156

Group type: EXPERIMENTAL
Intervention: Topical heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30829132

Group type: EXPERIMENTAL
Intervention: Complete intraureteral stent placement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional stent placement
Number of subjects: 80
Study: 29191819

Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg weekly
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 26169711

Group type: EXPERIMENTAL
Intervention: PLT mass-based transfusion guideline
Number of subjects: 100

Group type: COMPARATOR
Intervention: PLT count-based transfusion guideline
Number of subjects: 100
Study: 24469222

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 1200
Study: 22468755

Group type: EXPERIMENTAL
Intervention: Hyperoxic air (F(I)O(2) = 100%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normoxic air
Number of subjects: 10
Study: 20499120

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NF), 36 sessions
Number of subjects: 94

Group type: COMPARATOR
Intervention: Computerised attention skills training (AST)
Number of subjects: 94
Study: 17658415

Group type: EXPERIMENTAL
Intervention: Three weeks of hand-based splinting
Number of subjects: 26

Group type: COMPARATOR
Intervention: Free active motion
Number of subjects: 26
Study: 17175572

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15494617

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 to 12 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11192137

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% ophthalmic solution
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (natural tears lubricant eye drop)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Olopatadine and nedocromil
Number of subjects: 52
Study: 8922004

Group type: EXPERIMENTAL
Intervention: Topical tetracaine (4 mL)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Normal saline (4 mL)
Number of subjects: 57
Study: 1556948

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (600 kcal/d, 8 g nitrogen/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonketogenic diet (600 kcal/d, 8 g nitrogen/d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonketogenic diet
Number of subjects: 16
Study: 3998203

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30303299

Group type: EXPERIMENTAL
Intervention: Perceived line managers' support during the initiation and active phase
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Participation in the initiation and active phase
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Participation in the initiation phase
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Perceived line managers' support in the active phase
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Participation in the active phase
Number of subjects: 159
Study: 28485544

Group type: EXPERIMENTAL
Intervention: TC-325
Number of subjects: 20

Group type: COMPARATOR
Intervention: CCT
Number of subjects: 20
Study: 25642687

Group type: EXPERIMENTAL
Intervention: rMV (100Hz, 300‐500 μm; three applications per day, each lasting 10 minutes, for 3 consecutive days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation on contracted quadriceps (NV=non vibrated group)
Number of subjects: 40
Study: 24787529

Group type: EXPERIMENTAL
Intervention: Instruction to gesture
Number of subjects: 42

Group type: COMPARATOR
Intervention: No gesture instruction (Control)
Number of subjects: 42
Study: 23180062

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19733827

Group type: EXPERIMENTAL
Intervention: Closer 'distance' to the PPMW scenario
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substitute products (drugs in the same therapeutic class)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trust ratings for pharmacists and physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trust scores based on 'distance' from PPMW
Number of subjects: 0
Study: 16956912

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 1784

Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 1784
Study: 15132375

Group type: EXPERIMENTAL
Intervention: Small incision trabeculectomy avoiding Tenon's capsule (SIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin-C (MMC)
Number of subjects: 60
Study: 11281475

Group type: EXPERIMENTAL
Intervention: Coughing
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Valsalva
Number of subjects: 39
Study: 9040628

Group type: EXPERIMENTAL
Intervention: Aerosolized cyclosporine A (300 mg) for 10 consecutive days followed by maintenance of 3 days per week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aerosolized cyclosporine A
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional rescue therapy
Number of subjects: 16
Study: 7702337

Group type: EXPERIMENTAL
Intervention: Buflomedil infusion during arteriographies
Number of subjects: 16
Study: 3312030

Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g b.i.d.)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cefotaxime (2 g t.i.d. or more)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 30476916

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 500 mg, administered orally, 3 times per day for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 27434036

Group type: EXPERIMENTAL
Intervention: CT and CTX
Number of subjects: 257

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Further treatment for progressive disease
Number of subjects: 257
Study: 24090098

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (stationary cycling)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-aerobic exercise (stretching)
Number of subjects: 2
Study: 22139410

Group type: EXPERIMENTAL
Intervention: 1.6 g of pure βA reference solution (REF)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1.6 g in slow-release βA tablets (TAB)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study: 19926442

Group type: EXPERIMENTAL
Intervention: Interpretation Modification Program (IMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interpretation Control Condition (ICC)
Number of subjects: 0
Study: 18367385

Group type: EXPERIMENTAL
Intervention: SAT-diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: RO-diet
Number of subjects: 20
Study: 15917030

Group type: EXPERIMENTAL
Intervention: Special training condition for pediatric residents
Number of subjects: 1770

Group type: COMPARATOR
Intervention: Standard training condition for pediatric residents
Number of subjects: 1770
Study: 12162502

Group type: EXPERIMENTAL
Intervention: 400 microg SCT orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 800 microg SCT orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1200 microg SCT orally
Number of subjects: 8

Group type: COMPARATOR
Intervention: 10 microg SCT intravenous infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10467531

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (three 200-mg tablets per day)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 7782354

Group type: EXPERIMENTAL
Intervention: Lateral electrical surface stimulation
Number of subjects: 159

Group type: COMPARATOR
Intervention: Observation without treatment
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Prognostic model including Risser sign, apical level, and imbalance
Number of subjects: 159
Study: 2224350

Group type: EXPERIMENTAL
Intervention: Rotation-advancement technique
Number of subjects: 108

Group type: COMPARATOR
Intervention: Triangular flap technique
Number of subjects: 108
Study: 638842

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure
Number of subjects: 14

Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 14
Study: 31977640

Group type: EXPERIMENTAL
Intervention: MAL + FRU
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MAL + FRU + PEC + ALG
Number of subjects: 9

Group type: COMPARATOR
Intervention: MAL + GLU
Number of subjects: 9
Study: 30386886

Group type: EXPERIMENTAL
Intervention: mFOLFOX6‐bevacizumab plus ip PTX
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CapeOX‐bevacizumab plus ip PTX
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ip PTX
Number of subjects: 6
Study: 27932229

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily during weeks 1-3 of each 4-week cycle
Number of subjects: 573

Group type: COMPARATOR
Intervention: Placebo once daily during weeks 1-3 of each 4-week cycle
Number of subjects: 573
Study: 26052973

Group type: EXPERIMENTAL
Intervention: Vasopressin, steroids, and epinephrine (VSE) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epinephrine alone
Number of subjects: 0
Study: 23488277

Group type: EXPERIMENTAL
Intervention: DDD/R pacing mode
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: AAI/R pacing mode
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: VWVl/R pacing mode
Number of subjects: 117

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 117
Study: 20974751

Group type: EXPERIMENTAL
Intervention: Combined microfinance and gender training intervention
Number of subjects: 0